Androgen Reduction in Congenital Adrenal Hyperplasia
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Ann Arbor, Bethesda, Dallas, and Los Angeles, United StatesSee the 4 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Jan 2023
- Ended
- Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Abiraterone acetate
- Placebo
- Hydrocortisone
- Fludrocortisone
- Record updated
- 1 February 2023
- Why it stopped
- This study plan has halted and was withdrawn from the IRB.
Who can take part
- Age
- 2 years to 9 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Pre-pubescent girls (age 2 years [12 kg] to 8 years inclusive; skeletal age ≤9 years) or boys (age 2 years [12 kg] to 9 years inclusive; skeletal age ≤10 years)
- Confirmed classic 21-hydroxylase deficiency evident by genotype groups A, A1 or B, or by clinical course
- Requirement for standard of care fludrocortisone (any dose) and ≥10 mg/m2/day of hydrocortisone for at least 1 month prior to the study consent
- Morning serum androstenedione concentrations >1.5 x ULN after 7 days of dosing with doses of hydrocortisone required for physiologic replacement
- Informed consent
Who cannot take part
- Co-existent disease that may interfere with linear growth or that requires concomitant therapy that is likely to interfere with study procedures or results
- Treatment with potentially hepatotoxic medications, CYP2D6, strong inhibitors or inducers of CYP3A4
- Treatment with medications to affect puberty or synthesis of sex steroids, including gonadotropin releasing hormone agonists, aromatase inhibitors, or androgen receptor blockers
- Treatment with growth hormone
- Current or history of hepatitis from any etiology
- A history of a malabsorption syndrome
- Evidence of active malignancy
- Known allergies, hypersensitivity, or intolerance to abiraterone acetate or its excipients
- Abnormal liver function tests (transaminases>3X ULN)
- Abnormal renal function tests (BUN or creatinine >1.5 ULN)
- Significant anemia (hemoglobin < 12 g/dl)
- Evidence of central puberty: Tanner Stage >2 for breast development in girls or testicular volume >4 mL in boys, or random LH >0.3 mIU/mL
- Clinically significant ECG abnormality
Where in United States
- University of MichiganAnn Arbor, United States
- National Institutes of HealthBethesda, United States
- Children's Medical CenterDallas, United States
- Children's Hospital of Los AngelesLos Angeles, United States
About the trial
What the trial wants to find out
Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency tend to have elevated circulating levels of androgens, which can accelerate skeletal maturation and adversely impact adult height. Additionally, these children require supraphysiologic doses of hydrocortisone to suppress secretion of adrenal androgen precursors, and this treatment can retard linear growth. This study seeks to use oral abiraterone acetate (Zytiga)as an adjunct to approved CAH therapy (oral hydrocortisone and fludrocortisone) for pre-pubescent children with classic 21-hydroxylase deficiency in order to reduce daily requirement of hydrocortisone.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
Treatment: Placebo, Hydrocortisone, and Fludrocortisone
- Abiraterone acetateTreatment being tested
Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
Treatment: Abiraterone acetate, Hydrocortisone, and Fludrocortisone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency
- Record updated
- 1 February 2023